Sonnet BioTherapeutics

📍 Princeton, United States🗓 Founded 2011👥 15 employees💰 Last funded 2023
Biotechnology🌐 sonnetbio.com
Website LinkedIn
As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process. (NASDAQ: SONN)
3
Total investors
0
Early stage
0
Mid stage
2
Late stage
2011
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2018–2023 · investors recorded per year
201812020120231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Sonnet BioTherapeutics?
Sonnet BioTherapeutics has 3 investors on record on gritt.io and 2 late-stage investors.
When did Sonnet BioTherapeutics last raise funding?
The most recent investment in Sonnet BioTherapeutics recorded on gritt.io was in 2023.
When was Sonnet BioTherapeutics founded?
Sonnet BioTherapeutics was founded in 2011.
What industry is Sonnet BioTherapeutics in?
Sonnet BioTherapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Sonnet BioTherapeutics based?
Sonnet BioTherapeutics is headquartered in Princeton, United States.